MartinLutherKing
1 minute ago
The expanding clinical application as well as together with indication of CRISPR/Cas9, mounting preclinical and clinical trials, rise in technological advancement, presences of key players like Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, TransCode Therapeutics and many more, combina
Slojab
2 minutes ago
As of November 18, 2024, the issuer had 2,369,037,729 shares of its common stock issued and outstanding
Outstanding Shares 5,469,037,729 01/02/2025
Restricted 3,457,147,781 01/02/2025
Unrestricted 2,011,889,948 01/02/2025
On December 30, 2024, Two Hands Co